Posted by Michael Wonder on 30 Oct 2016
CADTH recommends the reimbursement of Taltz
25 October 2016 - The CADTH CDEC has recommend that ixekizumab be reimbursed for patients with moderate to severe plaque psoriasis
The CDEC has recommend that access the Taltz be limited to patients with a documented inadequate response, contraindication, or intolerance to conventional systemic therapies such as methotrexate and cyclosporin and that treatment should be discontinued if a response to treatment with ixekizumab has not been demonstrated after 12 weeks.
The CDEC has also a reduced price.
